Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Axogen, Inc.

Scott+Scott
Attorneys at Law LLP (“Scott+Scott”), a national shareholder and
consumer rights litigation firm, is notifying investors that a class
action lawsuit has been filed against Axogen, Inc. (“Axogen” or the
“Company”) (NASDAQ: AXGN) and other defendants, related to alleged
violations of federal securities laws. If you purchased Axogen common
stock in connection with the Company’s November 2017 Initial Public
Offering (“IPO”) or between August 7, 2017 and December 18, 2018, you
are encouraged to contact a Scott+Scott attorney at (844) 818-6980 for
more information.

The lawsuit alleges that Defendants made materially false and/or
misleading statements, as well as failed to disclose material adverse
facts about the Company’s business, operations, and prospects;
specifically: (1) Axogen aggressively increased prices to mask lower
sales; (2) Axogen’s pricing alienated customers and threatened the
Company’s future growth; (3) ambulatory surgery centers form a
significant part of the market for the Company’s products; (4) such
centers were especially sensitive to price increases; (5) Axogen was
dependent on a small number of surgeons whom the Company paid to
generate sales; (6) Axogen’s consignment model for inventory was
reasonably likely to lead to channel stuffing; (7) Axogen offered
purchase incentives to sales representatives to encourage channel
stuffing; (8) Axogen’s sales representatives were encouraged to backdate
revenue to artificially inflate metrics; (9) Axogen lacked adequate
internal controls to prevent such channel stuffing and backdating of
revenue; and (10) Axogen’s key operating metrics, such as number of
active accounts, were overstated.

On December 18, 2018, Seligman Investments issued a report stating,
among other things, that former employees allege channel stuffing and
backdating of revenue, that the number of active accounts may be
overstated by a factor of ten, and that aggressive annual price
increases had driven the Company’s revenue growth.

On this news, Axogen’s share price fell $6.17 per share – nearly 22% –
to close at $21.36 per share on December 18.

What You Can Do

If you purchased Axogen stock in the IPO or between August 7, 2017
and December 18, 2018, inclusive, or if you have questions about
this notice or your legal rights, please contact attorney Rhiana Swartz
at (844) 818-6980, or at [email protected].
The lead plaintiff deadline is March 11, 2019.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities,
antitrust, and employee retirement plan actions throughout the United
States. The firm represents pension funds, foundations, individuals, and
other entities worldwide with offices in New York, London, Connecticut,
California, and Ohio.

Attorney Advertising

View source version on businesswire.com: https://www.businesswire.com/news/home/20190117005567/en/